JP2002153457A - Medical equipment - Google Patents
Medical equipmentInfo
- Publication number
- JP2002153457A JP2002153457A JP2000354559A JP2000354559A JP2002153457A JP 2002153457 A JP2002153457 A JP 2002153457A JP 2000354559 A JP2000354559 A JP 2000354559A JP 2000354559 A JP2000354559 A JP 2000354559A JP 2002153457 A JP2002153457 A JP 2002153457A
- Authority
- JP
- Japan
- Prior art keywords
- rays
- ray
- glass
- medical
- conductive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011521 glass Substances 0.000 claims abstract description 52
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 24
- 239000011787 zinc oxide Substances 0.000 claims abstract description 16
- 230000005260 alpha ray Effects 0.000 claims abstract description 8
- 150000004706 metal oxides Chemical class 0.000 claims description 23
- 238000010894 electron beam technology Methods 0.000 claims description 14
- 230000001678 irradiating effect Effects 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 230000005250 beta ray Effects 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 230000005251 gamma ray Effects 0.000 claims description 5
- 229910003437 indium oxide Inorganic materials 0.000 claims description 5
- PJXISJQVUVHSOJ-UHFFFAOYSA-N indium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[In+3].[In+3] PJXISJQVUVHSOJ-UHFFFAOYSA-N 0.000 claims description 5
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 5
- 229910001887 tin oxide Inorganic materials 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 abstract description 28
- 230000002411 adverse Effects 0.000 abstract description 6
- 230000006866 deterioration Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710103182 Feruloyl esterase B Proteins 0.000 description 1
- 101001024616 Homo sapiens Neuroblastoma breakpoint family member 9 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102100037013 Neuroblastoma breakpoint family member 9 Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710134537 Probable feruloyl esterase B Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、放射線や電磁波な
どを利用して人体などの診断、治療などを行う医療設備
に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medical facility for diagnosing and treating a human body using radiation, electromagnetic waves, and the like.
【０００２】[0002]
【従来の技術】Ｘ線などを利用して病気の診断、治療を
行うことは広く行われており、現在の医療においても必
要不可欠なものであるが、近年の医療技術の進歩によ
り、放射線や電磁波などを利用した医療装置の開発はま
すます盛んとなり、実際の医療現場にも様々な医療装置
が導入されている。2. Description of the Related Art Diagnosis and treatment of diseases using X-rays and the like are widely performed, and are indispensable in current medical treatment. The development of medical devices using electromagnetic waves and the like has become more and more active, and various medical devices have been introduced to actual medical sites.
【０００３】放射線や電磁波などを長時間あるいは大量
に浴びると人体に悪影響が生じるため、これらの医療装
置は、放射線や電磁波などを透過しない分厚いコンクリ
ート壁で囲まれた専用の検査室内に設置されるととも
に、医療装置の操作員は安全性確保のために鉛などで形
成された安全服を着用している。When exposed to radiation or electromagnetic waves for a long time or in large quantities, the human body is adversely affected. Therefore, these medical devices are installed in a dedicated examination room surrounded by a thick concrete wall that does not transmit radiation and electromagnetic waves. At the same time, medical device operators wear safety clothing made of lead or the like to ensure safety.
【０００４】[0004]
【発明が解決しようとする課題】このような医療装置を
設置した医療設備において、人体に照射された放射線や
電磁波などは、人体を透過した後、検査室内で散乱する
が、γ線や中性子線などは、鉛の安全服やコンクリート
壁では完全に遮断することができないので、その一部が
周囲に漏洩するおそれがあり、医療装置の近くで長期間
に亘って作業を行う操作員や、検査室の周囲にいる第三
者への影響が無視できないことがある。In a medical facility equipped with such a medical device, radiation or electromagnetic waves applied to the human body are transmitted through the human body and then scattered in the examination room. Can not be completely shut off with lead safety clothing or concrete walls, some of which may leak to the surroundings. The impact on third parties around the room may not be negligible.
【０００５】本発明が解決しようとする課題は、人体に
悪影響を及ぼす放射線や電磁波などが漏洩することのな
い、安全性の高い医療設備を提供することにある。[0005] An object of the present invention is to provide a highly safe medical facility that does not leak radiation or electromagnetic waves that adversely affect the human body.
【０００６】[0006]
【課題を解決するための手段】本発明の医療設備は、紫
外線、赤外線、Ｘ線、α線、β線、γ線、電子線、中性
子線のいずれかを人体に照射して人体の診断、治療を行
う医療装置を含む医療設備であって、紫外線、赤外線、
Ｘ線、α線、β線、γ線、電子線、中性子線の通過経路
に、構成成分として導電性金属酸化物を含有するガラス
を配置したことを特徴とする。According to the medical equipment of the present invention, a human body is irradiated with any one of ultraviolet rays, infrared rays, X-rays, α-rays, β-rays, γ-rays, electron beams, and neutron rays to diagnose a human body. Medical equipment, including medical devices that provide treatment,
It is characterized in that glass containing a conductive metal oxide as a constituent component is disposed in a passage of X-rays, α-rays, β-rays, γ-rays, electron beams, and neutron beams.
【０００７】このような構成とすることにより、導電性
金属酸化物を含有するガラスが、医療装置から発生する
紫外線、赤外線、Ｘ線、α線、β線、γ線、電子線、中
性子線を効果的に遮断するので、これらの放射線や電磁
波などが漏洩することのない安全性の高い医療設備とな
る。また、このガラスは透明で、従来の紫外線遮蔽用の
表面コーティングガラスと異なり、ガラス自体が前記の
放射線や電磁波などの遮蔽機能を備えているため、表面
損傷による機能低下や経時変化が発生せず、耐久性も優
れている。[0007] With this configuration, the glass containing the conductive metal oxide can prevent ultraviolet rays, infrared rays, X-rays, α-rays, β-rays, γ-rays, electron rays, and neutron rays generated from the medical device. Since the shielding is effectively performed, the medical equipment has high safety without radiation or electromagnetic waves leaking. Also, this glass is transparent, unlike the conventional UV-shielding surface coating glass, because the glass itself has the above-mentioned radiation or electromagnetic wave shielding function, there is no deterioration or deterioration with time due to surface damage. Also, the durability is excellent.
【０００８】また、本発明の医療設備は、紫外線、赤外
線、Ｘ線、α線、β線、γ線、電子線、中性子線のいず
れかを人体に照射して人体の診断、治療を行う医療装置
を含む医療設備において、人体を保持するベッドに、構
成成分として導電性金属酸化物を含有するガラスを配置
した構成とすることもできる。[0008] The medical equipment of the present invention is a medical equipment for diagnosing and treating a human body by irradiating the human body with any one of ultraviolet rays, infrared rays, X-rays, α-rays, β-rays, γ-rays, electron beams and neutron rays. In a medical facility including a device, a configuration may be adopted in which glass containing a conductive metal oxide as a component is disposed on a bed for holding a human body.
【０００９】このような構成とすることにより、導電性
金属酸化物を含有するガラスが、人体を透過した紫外
線、赤外線、Ｘ線、α線、β線、γ線、電子線、中性子
線を効果的に遮断するので、これらの放射線や電磁波な
どが漏洩することのない安全性の高い医療設備となる。[0009] With this configuration, the glass containing the conductive metal oxide can effectively protect the human body from ultraviolet rays, infrared rays, X-rays, α-rays, β-rays, γ-rays, electron beams, and neutron rays. Since the radiation and electromagnetic waves are prevented from leaking, the medical equipment is highly safe and does not leak.
【００１０】ここで、前記導電性金属酸化物として、導
電性酸化亜鉛、導電性酸化錫、錫ドーピング酸化インジ
ウムのいずれかを使用することができる。これらの導電
性金属酸化物は、従来、紫外線、赤外線の遮蔽材として
ガラス表面にコーティングされていた物質であり、これ
らの物質をガラス構成成分中に含有させることにより、
紫外線、赤外線のみならず、Ｘ線、α線、β線、γ線、
電子線、中性子線を遮蔽する機能を発現し、ガラス自体
に導電性も発現するので、これらの放射線や電磁波の漏
洩を防止できるだけでなく、静電気による弊害も防止で
きる。Here, any of conductive zinc oxide, conductive tin oxide, and tin-doped indium oxide can be used as the conductive metal oxide. Conventionally, these conductive metal oxides are substances that have been coated on the glass surface as a shielding material for ultraviolet rays and infrared rays, and by including these substances in glass constituent components,
X-ray, α-ray, β-ray, γ-ray,
Since the function of shielding electron beams and neutron beams is exhibited, and the glass itself also exhibits conductivity, not only leakage of these radiations and electromagnetic waves can be prevented, but also adverse effects due to static electricity can be prevented.
【００１１】前記のように、導電性金属酸化物として
は、導電性酸化亜鉛、導電性酸化錫、錫ドーピング酸化
インジウムのいずれかを使用することができるが、とく
に導電性酸化亜鉛を含有させたガラスは、導電性酸化
錫、錫ドーピング酸化インジウムを含有させたガラスに
比べ、Ｘ線、α線、β線、γ線、電子線、中性子線を遮
蔽する機能に優れ、また、ガラスの透明度の劣化が極め
て少なく、着色による透明度の調整も容易である。As described above, any one of conductive zinc oxide, conductive tin oxide, and tin-doped indium oxide can be used as the conductive metal oxide. Particularly, the conductive metal oxide contains conductive zinc oxide. Glass is superior to glass containing conductive tin oxide and tin-doped indium oxide in shielding X-rays, α-rays, β-rays, γ-rays, electron beams, and neutrons. Deterioration is extremely small, and it is easy to adjust the transparency by coloring.
【００１２】このような導電性酸化亜鉛としては、アル
ミニウムやチタン、錫、これらの複合物などを含有する
ものがあるが、０．５〜１０重量％のアルミニウムを含
有する導電性酸化亜鉛は、とくにＸ線、α線、β線、γ
線、電子線、中性子線を遮蔽する機能に優れており、製
造工程におけるガラスとの混練も容易である。このよう
な導電性酸化亜鉛としては、ハクスイテック株式会社製
の導電性酸化亜鉛（商品名：２３Ｋ）が好適である。As such conductive zinc oxide, there is a conductive zinc oxide containing aluminum, titanium, tin, a composite thereof, and the like. The conductive zinc oxide containing 0.5 to 10% by weight of aluminum is, Especially X-ray, α-ray, β-ray, γ
It has an excellent function of shielding rays, electron beams and neutron rays, and is easily kneaded with glass in the production process. As such a conductive zinc oxide, a conductive zinc oxide (trade name: 23K) manufactured by Hakusuiteku Co., Ltd. is preferable.
【００１３】前述したガラスの構成成分としては、Ｓｉ
Ｏ2が６５〜８０％，Ｎａ2Ｏが１０〜２０％，ＣａＯが
５〜１５％，ＭｇＯが０〜１０％，Ｋ2Ｏが０〜５％，
Ａｌ2Ｏ3が０〜５％が基本成分であり，そのほかに、酸
素、珪素、ナトリウム、カルシウム、ホウ素、リチウ
ム、イオウ、アンチモン、アルミニウム、カリウム、チ
タン、バリウム、ジルコニウム、亜鉛、鉛、砒素、マグ
ネシウム、ストロンチウム、セリウム、セレン、鉄、コ
バルト、ニッケル、マンガン、モリブデン、クロムなど
を含有していても差し支えない。As a component of the above-mentioned glass, Si is used.
O 2 is 65-80% Na 2 O is 10 to 20% CaO is 5 to 15% MgO is 0% K 2 O 0 to 5%
Al 2 O 3 is 0 to 5% as a basic component, and oxygen, silicon, sodium, calcium, boron, lithium, sulfur, antimony, aluminum, potassium, titanium, barium, zirconium, zinc, lead, arsenic, It may contain magnesium, strontium, cerium, selenium, iron, cobalt, nickel, manganese, molybdenum, chromium, or the like.
【００１４】また、前記のガラス構成成分に対する導電
性金属酸化物の含有量は、０．１〜２５重量％の範囲、
望ましくは０．５〜１０重量％の範囲が好適である。導
電性金属酸化物の含有量が２５重量％を超えると、ガラ
ス構成成分の含有比率の自由度が低下するので、ガラス
本来の特徴を失うような弊害が生じることがあり、導電
性金属酸化物の含有量が０．１重量％より少なくなる
と、放射線や電磁波などの遮蔽機能および導電性が十分
に発現しない。Further, the content of the conductive metal oxide with respect to the above-mentioned glass component is in the range of 0.1 to 25% by weight,
Desirably, the range is 0.5 to 10% by weight. When the content of the conductive metal oxide exceeds 25% by weight, the degree of freedom of the content ratio of the glass constituent components is reduced, so that a disadvantage such as losing the inherent characteristics of the glass may occur, and the conductive metal oxide may be adversely affected. If the content of is less than 0.1% by weight, the function of shielding radiation and electromagnetic waves and the conductivity are not sufficiently exhibited.
【００１５】[0015]
【発明の実施の形態】図１は本発明の実施形態である医
療設備の一つとしてのＭＲＩ−ＣＴ装置を示す斜視図で
あり、図２は図１のＭＲＩ−ＣＴ装置の一部切欠側面
図、図３は図１のＭＲＩ−ＣＴ装置の動作説明図であ
る。なお、ＭＲＩ−ＣＴとは、Ｍａｇｎｅｔｉｃ Ｒｅ
ｓｏｎａｃｅ Ｉｍａｇｉｎｇ−Ｃｏｍｐｕｔｅｄ Ｔ
ｏｍｏｇｒａｐｈの略である。FIG. 1 is a perspective view showing an MRI-CT apparatus as one of medical facilities according to an embodiment of the present invention, and FIG. 2 is a partially cutaway side view of the MRI-CT apparatus in FIG. FIG. 3 and FIG. 3 are explanatory diagrams of the operation of the MRI-CT apparatus of FIG. In addition, MRI-CT is Magnetic Re
sonace Imaging-Computed T
Omograph.
【００１６】本実施形態のＭＲＩ−ＣＴ装置１０は、大
口径のソレノイド１１と、被験者１２を保持するベッド
１３と、被験者１２に磁気共鳴入力波を照射するγ線発
生器１４などで構成されている。ベッド１３の表面に
は、構成成分として導電性金属酸化物を含有するガラス
板１５が、ベッド長手方向にスライド可能に配置されて
おり、このガラス板１５をスライドさせることにより、
ガラス板１５上に横たわった被験者１２を大口径のソレ
ノイド１１内に出し入れすることができる。The MRI-CT apparatus 10 of this embodiment includes a large-diameter solenoid 11, a bed 13 for holding a subject 12, a γ-ray generator 14 for irradiating the subject 12 with a magnetic resonance input wave, and the like. I have. On the surface of the bed 13, a glass plate 15 containing a conductive metal oxide as a constituent component is disposed so as to be slidable in the longitudinal direction of the bed, and by sliding the glass plate 15,
The subject 12 lying on the glass plate 15 can be moved in and out of the large-diameter solenoid 11.
【００１７】このような構成により、ＭＲＩ−ＣＴ装置
１０は、ソレノイド１０の中に被験者１２を入れ、被験
者１２に垂直に照射する磁気共鳴入力波によって被験者
１２の断面をスキャンしながら得られた信号をＣＴ解析
し、被験者１２の診断を行うものである。With such a configuration, the MRI-CT apparatus 10 puts the subject 12 in the solenoid 10 and scans a cross section of the subject 12 with a magnetic resonance input wave irradiating the subject 12 vertically. Is subjected to CT analysis, and the subject 12 is diagnosed.
【００１８】ベッド１３の表面に配置されたガラス板１
５は、ＳｉＯ2を７１．８重量％，Ｎａ2Ｏを１３．３重
量％，ＣａＯを８．８重量％，ＭｇＯを３．５重量％，
Ｋ2Ｏを０．８重量％，Ａｌ2Ｏ3を１．７重量％，Ｆｅ2
Ｏ3を０．１重量％の割合で含むガラス原料粉粒体に、
ハクスイテック株式会社製の導電性酸化亜鉛（商品名：
２３−Ｋ）の粉末（平均粒径０．１〜０．２５μｍ）を
３〜１０重量％添加して、この粉粒体を予め６００〜１
３００℃に加熱した電気炉内で４時間加熱、溶融した
後、ステンレス鋼板上に流し出して室温まで徐冷し、さ
らに表面を研磨して得られたものであり、その厚さｔは
約１０ｍｍである。Glass plate 1 placed on the surface of bed 13
5 is 71.8% by weight of SiO 2 , 13.3% by weight of Na 2 O, 8.8% by weight of CaO, 3.5% by weight of MgO,
0.8% by weight of K 2 O, 1.7% by weight of Al 2 O 3 , Fe 2
Glass raw material powder containing 0.1% by weight of O 3
Conductive zinc oxide (trade name: Hakusui Tech Co., Ltd.)
23-K) (average particle size: 0.1 to 0.25 μm) is added in an amount of 3 to 10% by weight, and the powder is added in advance to 600 to 1%.
It is obtained by heating and melting in an electric furnace heated to 300 ° C. for 4 hours, flowing out onto a stainless steel plate, gradually cooling to room temperature, and further polishing the surface, and having a thickness t of about 10 mm. It is.
【００１９】このようにして製造されたガラス板１５
は、その構成成分として導電性金属酸化物の一つである
導電性酸化亜鉛（商品名：２３−Ｋ）を含有することで
紫外線、赤外線、Ｘ線、α線、β線、γ線、電子線、中
性子線を遮蔽する機能を有している。The glass plate 15 thus manufactured
Contains a conductive zinc oxide (trade name: 23-K), which is one of conductive metal oxides, as a component thereof, so that ultraviolet rays, infrared rays, X-rays, α-rays, β-rays, γ-rays, It has the function of shielding radiation and neutron radiation.
【００２０】したがって、ＭＲＩ−ＣＴ装置１０を用い
て被験者１２の診断を行う場合、図３に示すように、γ
線発生器１４から照射された磁気共鳴入力波（γ線）
は、被験者１２を透過した後、ベッド１３上のガラス板
１５によって完全に遮蔽され、ガラス板１５より下方へ
進行、散乱することがない。すなわち、ＭＲＩ−ＣＴ装
置１０は、放射線や電磁波などが漏洩するおそれがな
く、安全性も高いものとなる。また、ガラス板１５は導
電性を備えているため、帯電しにくく、静電気による弊
害も防止することができる。Therefore, when diagnosing the subject 12 using the MRI-CT apparatus 10, as shown in FIG.
Magnetic resonance input wave (γ-ray) emitted from the ray generator 14
After being transmitted through the subject 12, is completely shielded by the glass plate 15 on the bed 13, and does not travel below the glass plate 15 and scatter. In other words, the MRI-CT apparatus 10 has no risk of radiation or electromagnetic waves leaking, and has high safety. Further, since the glass plate 15 has conductivity, it is difficult to be charged, and the adverse effect due to static electricity can be prevented.
【００２１】本実施形態では、医療設備の一つとしてＭ
ＲＩ−ＣＴ装置１０について説明しているが、本発明は
これに限定するものではないので、放射線や電磁波など
を利用したその他の医療装置を含む医療設備に広く採用
することができる。また、ガラス板１５の配置場所は、
ベッド１３に限定するものではなく、放射線や電磁波な
どの通過経路に配置することができ、これによって放射
線や電磁波などが診断対象物以外の場所などへ漏洩する
を防止することができる。In this embodiment, M is one of the medical facilities.
Although the RI-CT apparatus 10 has been described, the present invention is not limited to this, and can be widely applied to medical facilities including other medical apparatuses using radiation, electromagnetic waves, and the like. The location of the glass plate 15 is as follows.
It is not limited to the bed 13 but can be arranged in a passage path of radiation, electromagnetic waves, etc., thereby preventing radiation, electromagnetic waves, etc. from leaking to places other than the diagnostic object.
【００２２】実際の医療現場において、ＭＲＩ−ＣＴ装
置１０は図４に示すように、コンクリート壁１６で囲ま
れた専用の検査室１７内に配置されており、その隣には
操作機器１８などが配置された操作室１９が設けられて
いる。そして、操作室１９内にいる操作員２０が操作機
器１８などを操作することによって、ＭＲＩ−ＣＴ装置
１０を用いて被験者１２の診断が行われる。At an actual medical site, the MRI-CT apparatus 10 is arranged in a dedicated examination room 17 surrounded by a concrete wall 16, as shown in FIG. An operation room 19 is provided. When the operator 20 in the operation room 19 operates the operation device 18 and the like, the subject 12 is diagnosed using the MRI-CT apparatus 10.
【００２３】この場合、検査室１７と操作室１９とを区
画するコンクリート壁１６の一部にガラス板１５と同じ
組成のガラス板２１を配置すれば、操作員２０はＭＲＩ
−ＣＴ装置１０から発生する放射線や電磁波などを受け
ることなく、操作室１９内からガラス板２１を通してＭ
ＲＩ−ＣＴ装置１０の状況を詳しく観察、確認しながら
操作することができる。In this case, if a glass plate 21 having the same composition as the glass plate 15 is placed on a part of the concrete wall 16 that partitions the inspection room 17 and the operation room 19, the operator 20 can use the MRI.
From the operation room 19 through the glass plate 21 without receiving radiation, electromagnetic waves, etc. generated from the CT apparatus 10
The user can operate while observing and confirming the state of the RI-CT apparatus 10 in detail.
【００２４】また、ガラス板２１自体が放射線や電磁波
などの遮蔽機能を備えていることにより、従来のガラス
窓より面積の広いガラス板２１を配置することが可能で
あるため、操作員２０は検査室１７内の様子を観察しや
すくなり、作業性も大幅に向上する。Further, since the glass plate 21 itself has a function of shielding radiation and electromagnetic waves, it is possible to arrange the glass plate 21 having a larger area than a conventional glass window. The inside of the room 17 can be easily observed, and the workability is greatly improved.
【００２５】さらに、ガラス板１５，２１は透明で、従
来の紫外線遮蔽用の表面コーティングガラスと異なり、
ガラス自体が放射線や電磁波などの遮蔽機能を備えてい
るため、表面損傷による機能低下や経時変化が発生せ
ず、透明度の劣化が極めて少なく、耐久性も優れてい
る。Further, the glass plates 15 and 21 are transparent and different from the conventional surface coating glass for shielding ultraviolet rays,
Since the glass itself has a function of shielding radiation, electromagnetic waves, and the like, there is no deterioration or deterioration with time due to surface damage, the transparency is extremely low, and the durability is excellent.
【００２６】[0026]
【発明の効果】本発明により、以下に示す効果を奏す
る。According to the present invention, the following effects can be obtained.
【００２７】（１）紫外線、赤外線、Ｘ線、α線、β
線、γ線、電子線、中性子線のいずれかを人体に照射し
て人体の診断、治療を行う医療設備において、これらの
放射線、電磁波の通過経路に、構成成分として導電性金
属酸化物を含有するガラスを配置することにより、この
ガラスがこれらの放射線、電磁波を効果的に遮断するの
で、放射線や電磁波などが漏洩することがなくなり、安
全性が高まる。(1) UV, infrared, X-ray, α-ray, β
In medical facilities for diagnosing and treating the human body by irradiating the human body with any of rays, γ-rays, electron beams, or neutron rays, these radiation and electromagnetic wave passages contain conductive metal oxide as a component By arranging the glass, the glass effectively blocks these radiations and electromagnetic waves, so that the radiations and electromagnetic waves do not leak and the safety is enhanced.
【００２８】（２）紫外線、赤外線、Ｘ線、α線、β
線、γ線、電子線、中性子線のいずれかを人体に照射し
て人体の診断、治療を行う医療設備において、人体を保
持するベッドに、構成成分として導電性金属酸化物を含
有するガラスを配置することにより、このガラスが人体
を透過したこれらの放射線、電磁波を効果的に遮断する
ので、放射線や電磁波などが漏洩することがなくなり、
安全性が高まる。(2) UV, infrared, X-ray, α-ray, β
In a medical facility for diagnosing and treating the human body by irradiating the human body with any of rays, γ-rays, electron beams, and neutron rays, a bed containing a conductive metal oxide as a component is placed on a bed holding the human body. By arranging, this glass effectively blocks these radiation and electromagnetic waves transmitted through the human body, so that radiation and electromagnetic waves do not leak,
Increases safety.
【００２９】（３）導電性金属酸化物として、導電性酸
化亜鉛、導電性酸化錫、錫ドーピング酸化インジウムの
いずれかを使用することにより、紫外線、赤外線、Ｘ
線、α線、β線、γ線、電子線、中性子線を遮蔽する機
能を発現し、ガラス自体に導電性も発現するので、放射
線や電磁波の漏洩防止機能および静電気防止機能がさら
に高まる。また、導電性酸化亜鉛を含有するガラスは透
明度の劣化が極めて少なく、着色による透明度の調整も
容易となる。(3) By using any of conductive zinc oxide, conductive tin oxide, and tin-doped indium oxide as the conductive metal oxide, ultraviolet, infrared, X
Since the function of shielding rays, α-rays, β-rays, γ-rays, electron beams, and neutron rays is exhibited, and the glass itself also exhibits conductivity, the function of preventing leakage of radiation and electromagnetic waves and the function of preventing static electricity are further enhanced. Further, the glass containing conductive zinc oxide has very little deterioration in transparency, and the adjustment of the transparency by coloring becomes easy.
【００３０】（４）導電性金属酸化物として、０．５〜
１０重量％のアルミニウムを含有する導電性酸化亜鉛を
使用することにより、Ｘ線、α線、β線、γ線、電子
線、中性子線を遮蔽する機能が高まり、製造工程におけ
るガラスとの混練も容易となる。(4) As the conductive metal oxide, 0.5 to 0.5
By using conductive zinc oxide containing 10% by weight of aluminum, the function of shielding X-rays, α-rays, β-rays, γ-rays, electron beams, and neutron rays is enhanced, and kneading with glass in the manufacturing process is also possible. It will be easier.
【００３１】（５）ガラス構成成分に対する導電性金属
酸化物の含有量を０．１〜２５重量％の範囲とすること
により、ガラス本来の特徴を失うことなく、放射線や電
磁波などの遮蔽機能および導電性を発現させることがで
きる。(5) By setting the content of the conductive metal oxide to the glass component in the range of 0.1 to 25% by weight, the function of shielding radiation and electromagnetic waves and the like can be maintained without losing the inherent characteristics of glass. Conductivity can be exhibited.
【図１】 実施形態である医療設備の一つとしてのＭＲ
Ｉ−ＣＴ装置を示す斜視図である。FIG. 1 is an MR as one of medical equipment according to an embodiment.
It is a perspective view showing an I-CT device.
【図２】 図１のＭＲＩ−ＣＴ装置の一部切欠側面図で
ある。FIG. 2 is a partially cutaway side view of the MRI-CT apparatus of FIG.
【図３】 図１のＭＲＩ−ＣＴ装置の動作説明図であ
る。FIG. 3 is an operation explanatory diagram of the MRI-CT apparatus of FIG. 1;
【図４】 図１のＭＲＩ−ＣＴ装置の配置図である。FIG. 4 is a layout diagram of the MRI-CT apparatus of FIG. 1;
１０ ＭＲＩ−ＣＴ装置 １１ ソレノイド １２ 被験者 １３ ベッド １４ γ線発生器 １５，２１ ガラス板 １６ コンクリート壁 １７ 検査室 １８ 操作機器 １９ 操作室 ２０ 操作員 DESCRIPTION OF SYMBOLS 10 MRI-CT apparatus 11 Solenoid 12 Subject 13 Bed 14 γ-ray generator 15, 21 Glass plate 16 Concrete wall 17 Inspection room 18 Operation equipment 19 Operation room 20 Operator
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ｃ０３Ｃ 3/087 Ｃ０３Ｃ 3/087 4/14 4/14 Ｇ２１Ｆ 1/06 Ｇ２１Ｆ 1/06 (72)発明者 加藤 晴己 大阪府茨木市耳原１−１−45 レシェンテ 耳原303号 (72)発明者 山辺 誠二郎 福岡県飯塚市大字立岩1077−171 Ｆターム(参考） 4C082 AC02 AC03 AC05 AC06 AC07 AE01 AL01 AR01 AT04 PA01 PA03 PC09 PG17 PJ01 4C093 CA33 ED02 EE11 4G062 AA01 BB01 CC01 DA06 DA07 DB01 DB02 DB03 DC01 DC02 DC03 DD01 DE01 DE02 DE03 DE04 DF01 DF02 DF03 EA01 EA02 EA03 EB04 EC01 EC02 EC03 ED01 ED02 ED03 EE01 EE02 EE03 EE04 EF01 EF02 EF03 EG01 EG02 EG03 FA01 FA10 FB01 FB02 FB03 FC01 FC02 FC03 FD01 FE01 FE02 FE03 FE04 FF01 FG01 FH01 FJ01 FK01 FL01 FL02 FL03 GA01 GA10 GB01 GB02 GB03 GC01 GC02 GC03 GD01 GE01 HH01 HH03 HH05 HH06 HH07 HH08 HH09 HH10 HH11 HH12 HH13 HH15 HH17 HH20 JJ01 JJ03 JJ04 JJ05 JJ07 JJ10 KK01 KK03 KK05 KK07 KK10 MM40 NN12 NN13 NN14 NN24 NN35 NN40 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) C03C 3/087 C03C 3/087 4/14 4/14 G21F 1/06 G21F 1/06 (72) Inventor Harumi Kato 1-1-45 Amihara, Ibara, Ibaraki-shi, Osaka No. 303, Reshente Minohara (72) Inventor Seijiro Yamabe 1077-171, Tateiwa, Oaza, Iizuka-shi, Fukuoka F term (reference) 4C082 AC02 AC03 AC05 AC06 AC07 AE01 AL01 AR01 AT04 PA01 PA03 PC09 PG17 PJ01 4C093 CA33 ED02 EE11 4G062 AA01 BB01 CC01 DA06 DA07 DB01 DB02 DB03 DC01 DC02 DC03 DD01 DE01 DE02 DE03 DE04 DF01 DF02 DF03 EA01 EA02 EA03 FAEB EB04 EC01 EC02 EC03 ED01 ED03 EE03 EE03 EE03 EE03 FB03 FC01 FC02 FC03 FD01 FE01 FE02 FE03 FE04 FF01 FG01 FH01 FJ01 FK01 FL01 FL02 FL03 GA01 GA10 GB01 GB02 GB03 GC01 GC02 GC03 GD01 GE01 HH01 HH03 HH05 H H06 HH07 HH08 HH09 HH10 HH11 HH12 HH13 HH15 HH17 HH20 JJ01 JJ03 JJ04 JJ05 JJ07 JJ10 KK01 KK03 KK05 KK07 KK10 MM40 NN12 NN13 NN14 NN24 NN35 NN40
Claims (5)
線、電子線、中性子線のいずれかを人体に照射して人体
の診断、治療を行う医療装置を含む医療設備であって、
前記紫外線、赤外線、Ｘ線、α線、β線、γ線、電子
線、中性子線の通過経路に、構成成分として導電性金属
酸化物を含有するガラスを配置したことを特徴とする医
療設備。1. ultraviolet, infrared, X-ray, α-ray, β-ray, γ
X-ray, electron beam, medical equipment including a medical device for diagnosing the human body by irradiating any of the neutron beam, treatment,
A medical facility, wherein a glass containing a conductive metal oxide as a constituent component is disposed in a passage of the ultraviolet light, infrared light, X-ray, α-ray, β-ray, γ-ray, electron beam, and neutron beam.
線、電子線、中性子線のいずれかを人体に照射して人体
の診断、治療を行う医療装置を含む医療設備であって、
前記人体を保持するベッドに、構成成分として導電性金
属酸化物を含有するガラスを配置したことを特徴とする
医療設備。2. Ultraviolet, infrared, X-ray, α-ray, β-ray, γ
X-ray, electron beam, medical equipment including a medical device for diagnosing the human body by irradiating any of the neutron beam, treatment,
A medical facility, wherein a glass containing a conductive metal oxide as a component is disposed on a bed for holding the human body.
鉛、導電性酸化錫、錫ドーピング酸化インジウムのいず
れかである請求項１または２記載の医療設備。3. The medical facility according to claim 1, wherein the conductive metal oxide is one of conductive zinc oxide, conductive tin oxide, and tin-doped indium oxide.
重量％のアルミニウムを含有する導電性酸化亜鉛である
請求項１または２記載の医療設備。4. The method according to claim 1, wherein the conductive metal oxide is 0.5 to 10
The medical equipment according to claim 1, wherein the medical equipment is a conductive zinc oxide containing aluminum by weight.
ス原料の０．１〜２５重量％である請求項１ないし４の
いずれかに記載の医療設備。5. The medical facility according to claim 1, wherein the content of the conductive metal oxide is 0.1 to 25% by weight of the glass raw material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000354559A JP2002153457A (en) | 2000-11-21 | 2000-11-21 | Medical equipment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000354559A JP2002153457A (en) | 2000-11-21 | 2000-11-21 | Medical equipment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002153457A true JP2002153457A (en) | 2002-05-28 |
Family
ID=18827122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000354559A Pending JP2002153457A (en) | 2000-11-21 | 2000-11-21 | Medical equipment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002153457A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006120941A1 (en) | 2005-05-09 | 2006-11-16 | Shiseido Company, Ltd. | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin |
| JP2008019134A (en) * | 2006-07-14 | 2008-01-31 | Agc Techno Glass Co Ltd | Ultraviolet-ray absorbing glass for fluorescent lamp, glass tube for fluorescent lamp, and method for manufacturing the ultraviolet-ray absorbing glass for fluorescent lamp |
| KR100958791B1 (en) | 2008-04-28 | 2010-05-18 | 중앙대학교 산학협력단 | A device for a medical imaging |
| JP2011092423A (en) * | 2009-10-29 | 2011-05-12 | Sumitomo Heavy Ind Ltd | Accelerated particle irradiation equipment and structure of storage chamber |
| JP2011092424A (en) * | 2009-10-29 | 2011-05-12 | Sumitomo Heavy Ind Ltd | Accelerated particle irradiation equipment |
| JP2013081602A (en) * | 2011-10-07 | 2013-05-09 | High Energy Accelerator Research Organization | Method and apparatus for preventing radiation exposure |
| KR20160029647A (en) * | 2014-09-05 | 2016-03-15 | 스미도모쥬기가이고교 가부시키가이샤 | Neutron-ray capture therapy system |
| KR101731436B1 (en) * | 2013-02-27 | 2017-04-28 | 스미도모쥬기가이고교 가부시키가이샤 | Neutron capture therapy system |
| WO2018176686A1 (en) * | 2017-03-29 | 2018-10-04 | 南京中硼联康医疗科技有限公司 | Radiation irradiation system and positioning component for radiation irradiation system |
| WO2023090216A1 (en) * | 2021-11-16 | 2023-05-25 | 国立大学法人京都大学 | Neutron shielding material and method for producing same |
-
2000
- 2000-11-21 JP JP2000354559A patent/JP2002153457A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006120941A1 (en) | 2005-05-09 | 2006-11-16 | Shiseido Company, Ltd. | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin |
| JP2008019134A (en) * | 2006-07-14 | 2008-01-31 | Agc Techno Glass Co Ltd | Ultraviolet-ray absorbing glass for fluorescent lamp, glass tube for fluorescent lamp, and method for manufacturing the ultraviolet-ray absorbing glass for fluorescent lamp |
| KR100958791B1 (en) | 2008-04-28 | 2010-05-18 | 중앙대학교 산학협력단 | A device for a medical imaging |
| JP2011092423A (en) * | 2009-10-29 | 2011-05-12 | Sumitomo Heavy Ind Ltd | Accelerated particle irradiation equipment and structure of storage chamber |
| JP2011092424A (en) * | 2009-10-29 | 2011-05-12 | Sumitomo Heavy Ind Ltd | Accelerated particle irradiation equipment |
| JP2013081602A (en) * | 2011-10-07 | 2013-05-09 | High Energy Accelerator Research Organization | Method and apparatus for preventing radiation exposure |
| KR101731436B1 (en) * | 2013-02-27 | 2017-04-28 | 스미도모쥬기가이고교 가부시키가이샤 | Neutron capture therapy system |
| KR20160029647A (en) * | 2014-09-05 | 2016-03-15 | 스미도모쥬기가이고교 가부시키가이샤 | Neutron-ray capture therapy system |
| KR101670017B1 (en) | 2014-09-05 | 2016-10-27 | 스미도모쥬기가이고교 가부시키가이샤 | Neutron-ray capture therapy system |
| WO2018176686A1 (en) * | 2017-03-29 | 2018-10-04 | 南京中硼联康医疗科技有限公司 | Radiation irradiation system and positioning component for radiation irradiation system |
| EP3527261A4 (en) * | 2017-03-29 | 2019-11-13 | Neuboron Medtech Ltd. | Radiation irradiation system and positioning component for radiation irradiation system |
| JP2020503164A (en) * | 2017-03-29 | 2020-01-30 | 南京中硼▲聯▼康医▲療▼科技有限公司Ｎｅｕｂｏｒｏｎ Ｍｅｄｔｅｃｈ Ｌｔｄ． | Irradiation system and positioning assembly for the irradiation system |
| US11338155B2 (en) | 2017-03-29 | 2022-05-24 | Neuboron Medtech Ltd. | Radiation irradiation system and positioning assembly for radiation irradiation system |
| WO2023090216A1 (en) * | 2021-11-16 | 2023-05-25 | 国立大学法人京都大学 | Neutron shielding material and method for producing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boukhris et al. | Photon and electron attenuation parameters of phosphate and borate bioactive glasses by using Geant4 simulations | |
| Limbacher et al. | Radiation safety in the practice of cardiology | |
| Almatari et al. | Photon and neutron shielding characteristics of samarium doped lead alumino borate glasses containing barium, lithium and zinc oxides determined at medical diagnostic energies | |
| McCaffrey et al. | Radiation shielding materials and radiation scatter effects for interventional radiology (IR) physicians | |
| JP2002153457A (en) | Medical equipment | |
| Kim et al. | Physical analysis of the shielding capacity for a lightweight apron designed for shielding low intensity scattering X-rays | |
| Al-Hadeethi et al. | Preparation and radiation attenuation properties of ceramic ball clay enhanced with micro and nano ZnO particles | |
| Tijani et al. | The influence of TeO2 and Bi2O3 on the shielding ability of lead-free transparent bismuth tellurite glass at low gamma energy range | |
| Jain | Radiation in medical practice & health effects of radiation: rationale, risks, and rewards | |
| Thumwong et al. | Enhanced X-ray shielding properties of NRL gloves with nano-Bi2O3 and their mechanical properties under aging conditions | |
| EP1939147B2 (en) | Radiation shielding glass and method for manufacture thereof | |
| Norris | Radiation safety in fluoroscopy.(Directed Reading) | |
| Balter | Radiation safety in the cardiac catheterization laboratory: basic principles | |
| Al-Buriahi et al. | Klein–Nishina formula and Monte Carlo method for evaluating the gamma attenuation properties of Zn, Ba, Te and Bi elements | |
| Tsapaki et al. | Patient and staff radiation exposure during endoscopic retrograde cholangio-pancreatography: eight years of dose monitoring | |
| Hassan et al. | A versatile program for the calculation of linear accelerator room shielding | |
| Persson | Radiation hazards | |
| Itas et al. | Radiation shielding properties of 35-XBaO-15CaO-5Al2O3-10B2O3-35SiO2-XBNNT (X= 5, 10, 15, 20) glass reinforced with boron nitride nanotubes | |
| Kim et al. | Radiation Safety | |
| Kwon et al. | Performance and feasibility evaluation for radiation shielding of metal oxides: Monte Carlo simulation | |
| Urfa et al. | Study of Alternative Radiation Material Shielding for Gamma Radiation using Monte Carlo Simulation | |
| El-Khatib et al. | Novel composite based on silicone rubber and a nano mixture of SnO2, Bi2O3, and CdO for gamma radiation protection | |
| Berg | Radiation exposure to personnel during CT procedures | |
| Hussein | Optical and Shielding Parameters of Tellurite Glass with Composition 80TeO2-5Nb2O5-10ZnO-5LiF for Medical Application: Theoretical Investigation | |
| Adhikari | Current status of radiation protection in different hospitals in Nepal |